This pharmacologic inhibition of NF-kB, JNK and CYP2E1 expression and p38 phosphorylation may contribute to the suppression of α-SMA expression in the liver (Fig. 6e), leading to attenuation of CCl4-induced liver fibrosis. Here, NFKB1 is linked to Hepatic fibrosis.